Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million
Thoma Bravo to acquire Kneat for C$6.50/sh cash, a ~40% premium to unaffected and ~20% to last close, taking the digital validation leader private.
Kneat has entered into a definitive arrangement agreement to be acquired by Thoma Bravo in an all-cash transaction at C$6.50 per share, valuing the company at approximately C$650 million on a fully diluted basis. The offer represents a ~40% premium to the unaffected closing price on May 8, 2026, and ~20% to the June 5, 2026 closing price. The deal is unanimously approved by the Board and recommended by a Special Committee, supported by fairness opinions from CIBC and ATB Cormark. Directors and officers holding ~21.9% of outstanding shares have committed to vote in favor. The transaction is subject to shareholder (two-thirds majority, majority of minority) and court approval, with a special meeting expected by early August 2026 and closing targeted for Q3 2026. A C$22.6 million break fee is payable in limited circumstances. Upon closing, Kneat will delist from the TSX and become a privately held company.
This is a definitive, board-approved acquisition at a clear cash premium. It transforms Kneat from a public growth company with execution risk to a private entity, providing shareholders with immediate, certain value. The market had already started pricing in a deal following the strategic review disclosure, but the final offer still delivers incremental upside. The premium over the unaffected price is substantial (40%), and the structure (all cash, limited conditions, insider voting support) reduces deal risk. The news is strongly material and rerates the company as a takeout target.
Kneat Solutions Inc. provides a cloud-based digital validation platform (Kneat Gx) used primarily by life sciences companies to digitize qualification, validation, and compliance documentation. The company operates a SaaS model with high recurring revenue (ARR C$76.4M at Q1 2026). Its customer base includes 8 of the top 10 global pharmaceutical manufacturers. Headquartered in Canada, Kneat is listed on the TSX under the symbol KSI.